Celldex's Q3 Loss: Big Spend on Barzolvolimab, Positive Results

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded11 Nov 2025

Publisherfeeds.acast.com ↗

Handlerec:2198213

Show notes

Celldex Therapeutics Q3 earnings missed expectations, reporting a larger loss than predicted due to increased R&D spending, particularly on barzolvolimab, a drug targeting mast cells. Despite the earnings miss, the stock price remained stable. The company reported no revenue and ended the quarter with $583.2 million in cash, enough to operate through 2027. They also shared positive results from a Phase Two study of barzolvolimab and plan to start a larger Phase Three study in December 2025. Additionally, Celldex is developing another drug, CDX-622, which showed promising results in its Phase One study.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.